Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Medicare’s Part D coverage of the top three semaglutide-containing medications prescribed for diabetes—Ozempic, Rybelsus, and Mounjaro—added up to $5.7 billion in 2022.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday. The ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Medicare agrega a Ozempic, Wegovy y otros medicamentos a su lista para reducir precios El medicamento inyectable Ozempic, el 1 de julio de 2023, en Houston. (Foto AP/David J. Phillip, Archivo) ...

WASHINGTON — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers ...

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.